LUND, Sweden, Nov. 22, 2018 /PRNewswire/ -- Camurus announced today that the European Commission (EC) has approved weekly and monthly Buvidal® (prolonged release buprenorphine) for the treatment of ...
Phase 3 post-hoc analysis indicates less fentanyl and overall illicit opioid use for weekly/monthly buprenorphine depots versus daily standard treatment in a difficult to treat patient population LUND ...
Buvidal ® is the first long-acting medicine approved in the EU for the treatment of opioid dependence in adults and adolescents Camurus announced today that the European Commission has granted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback